Literature DB >> 28642034

Cyclooxygenase-2 promotes pulmonary intravascular macrophage accumulation by exacerbating BMP signaling in rat experimental hepatopulmonary syndrome.

Chang Liu1, Jing Gao1, Bing Chen2, Lin Chen1, Karine Belguise3, Weifeng Yu4, Kaizhi Lu1, Xiaobo Wang5, Bin Yi6.   

Abstract

BACKGROUND AND AIMS: One central factor in hepatopulmonary syndrome (HPS) pathogenesis is intravascular accumulation of activated macrophages in small pulmonary arteries. However, molecular mechanism underlying the macrophage accumulation in HPS is unknown. In this study, we aimed to explore whether elevated COX-2 induces the Bone morphogenic protein-2 (BMP-2)/Crossveinless-2 (CV-2) imbalance and then activation of BMP signaling pathway promotes the macrophage accumulation in Common Bile Duct Ligation (CBDL) rat lung.
METHODS: The COX-2/PGE2 signaling activation, the BMP-2/CV-2 imbalance and the activation of Smad1 were evaluated in CBDL rat lung and in cultured pulmonary microvascular endothelial cells (PMVECs) under the HPS serum stimulation. The effects of Parecoxib (COX-2 inhibitor), BMP-2 and CV-2 recombinant proteins on 4-week CBDL rat lung were determined, respectively.
RESULTS: The COX-2/PGE2 signaling pathway was activated in CBDL rat lung in vivo and PMVECs in vitro, which was due to the activation of NF-κB P65. The inhibition of COX-2 by Parecoxib reduced macrophage accumulation, decreased lung angiogenesis and improved HPS. Meanwhile, the CBDL rat lung secreted more BMP-2 but less CV-2, and the imbalance between BMP-2 and CV-2 exacerbated the BMP signaling activation thus promoting the macrophage accumulation and lung angiogenesis. The BMP-2/CV-2 imbalance is dependent on the COX-2/PGE2 signaling pathway, and thus the effects of this imbalance can be reversed by adminstration of Parecoxib.
CONCLUSION: Our findings indicate that inhibition of COX-2 by parecoxib can improve the HPS through the repression of BMP signaling and macrophage accumulation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone morphogenic protein-2; Crossveinless-2; Cyclooxygenase-2; Hepatopulmonary syndrome

Mesh:

Substances:

Year:  2017        PMID: 28642034     DOI: 10.1016/j.bcp.2017.06.117

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

2.  Transient receptor potential ankyrin-1 causes rapid bronchodilation via nonepithelial PGE2.

Authors:  Brenda J Marsh; Allison D Fryer; David B Jacoby; Matthew G Drake
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-04-01       Impact factor: 5.464

Review 3.  Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.

Authors:  Ioana Mozos; Clemens Malainer; Jarosław Horbańczuk; Cristina Gug; Dana Stoian; Constantin Tudor Luca; Atanas G Atanasov
Journal:  Front Immunol       Date:  2017-08-31       Impact factor: 7.561

4.  Shenqi Fuzheng Injection impairs bile duct ligation-induced cholestatic liver injury in vivo.

Authors:  Fei Cao; Peng Liu; Xianbin Zhang; Yanfen Hu; Xin Dong; Haidong Bao; Lingkai Kong; Lei Wang; Peng Gong
Journal:  Biosci Rep       Date:  2019-01-25       Impact factor: 3.840

5.  Krüppel-like factor 6 mediates pulmonary angiogenesis in rat experimental hepatopulmonary syndrome and is aggravated by bone morphogenetic protein 9.

Authors:  Yihui Yang; Hongfu Yu; Congwen Yang; Yunfei Zhang; Xiangfa Ai; Xiaobo Wang; Kaizhi Lu; Bin Yi
Journal:  Biol Open       Date:  2019-06-26       Impact factor: 2.422

6.  MiR145-5p inhibits proliferation of PMVECs via PAI-1 in experimental hepatopulmonary syndrome rat pulmonary microvascular hyperplasia.

Authors:  Yang Chen; Congwen Yang; Yujie Li; Lin Chen; Yong Yang; Karine Belguise; Xiaobo Wang; Kaizhi Lu; Bin Yi
Journal:  Biol Open       Date:  2019-11-04       Impact factor: 2.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.